2024
Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
Cohen-Nowak A, Coltoff A, Patel A, Atallah E, El Kettani M, Wang J, Symes E, Venkataraman G, Siddon A, Giever E, Shallis R, Altman J, Bell-Burdett K, Badar T, Aqil B, Abaza Y. Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study. Blood 2024, 144: 2801-2801. DOI: 10.1182/blood-2024-199377.Peer-Reviewed Original ResearchALL-directed therapySubtypes of acute leukemiaOverall survivalIntensive chemotherapyAcute lymphoblastic leukemiaAcute myeloid leukemiaAllo-SCTOS ratesAcute leukemiaFLT3-ITDBridge to allogeneic stem cell transplantationBlast populationCNS diseaseMedian duration of responseAllogeneic stem cell transplantationMulti-center retrospective studyResistant to traditional therapiesAML-directed therapyDiagnosis of MPALMedian overall survivalIncomplete count recoveryInduce durable remissionsDuration of responseStem cell transplantationAllo-SCT recipientsThe Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Shah K, El Kettani M, Narra R, Mims A, Coltoff A, Medawar G, Hisrich B, Shallis R, Hunter C, Kota V, Othman T, Jonas B, Desai S, Sacchi de Camargo Correia G, Patel A, Duvall A, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M, Badar T. The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 4184-4184. DOI: 10.1182/blood-2024-205812.Peer-Reviewed Original ResearchCNS relapseCentral nervous system involvementPh+ acute lymphoblastic leukemiaRelapse free survivalTyrosine kinase inhibitorsAcute lymphoblastic leukemiaIncidence of CNS relapseMedian relapse free survivalCentral nervous systemCNS diseaseOverall survivalAllo-HCTIntrathecal chemotherapyWhite blood cellsIntensive chemotherapyPost-relapseT315I mutationBaseline characteristicsMedian time to CNS relapseAllogeneic stem cell transplantationAssociated with significant toxicityIncidence of CNS diseaseMedian white blood cellAdequate CNS prophylaxisCentral nervous system penetrationImpact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study
Badar T, Narra R, Mims A, Heckman M, Shallis R, Fahad S, Hunter C, Kota V, Othman T, Jonas B, Desai S, de Camargo Correia G, Patel A, DuVall A, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study. American Journal Of Hematology 2024, 99: 2388-2391. PMID: 39253997, DOI: 10.1002/ajh.27475.Peer-Reviewed Original ResearchIntensive chemotherapyPhiladelphia chromosome-positive acute lymphoblastic leukemiaAllogeneic stem cell transplantationFirst-generation TKIsStem cell transplantationSurvival of patientsAcute lymphoblastic leukemiaMulti-institutional studyAllo-HCTPropensity score matchingRegimen intensityCell transplantationLymphoblastic leukemiaMultivariate analysis
2023
Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation
Badar T, Narra R, Mims A, Shallis R, De Camargo Correia G, Hunter C, Kota V, Desai S, Patel A, Duvall A, Palmisiano N, Curran E, Zulfa O, Advani A, Atallah E, Litzow M. Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation. Blood 2023, 142: 1464. DOI: 10.1182/blood-2023-188188.Peer-Reviewed Original ResearchWhite blood cell countRelapse-free survivalAllogeneic stem cell transplantationP210 fusion proteinMedian overall survivalOverall survivalMeasurable residual diseaseStem cell transplantationAcute lymphoblastic leukemiaIntensive chemotherapyAllo-HCTAdult PhCell transplantationMulticenter studyPhiladelphia chromosome-positive acute lymphoblastic leukemia patientsExact testPositive acute lymphoblastic leukemia patientsMedian white blood cell countPhiladelphia chromosome-positive acute lymphoblastic leukemiaMedian relapse-free survivalAcute lymphoblastic leukemia patientsCG abnormalities
2021
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data
Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplantation 2021, 56: 1998-2004. PMID: 33824440, DOI: 10.1038/s41409-021-01279-w.Peer-Reviewed Original ResearchConceptsOverall survivalCumulative incidenceAllogeneic hematopoietic stem cell transplantationB-cell acute lymphoblastic leukemiaHematopoietic stem cell transplantationAcute lymphocytic leukemia patientsStem cell transplantationAcute lymphoblastic leukemiaLymphocytic leukemia patientsMulti-institutional studyReal-world analysisSevere cGVHDFree survivalClinical outcomesCell transplantationLymphoblastic leukemiaMulti-center dataClinical trialsAlloHCTLeukemia patientsBlinatumomabPatientsSurvivalIncidenceSubsequent salvage
2020
Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer 2020, 127: 1039-1048. PMID: 33259056, DOI: 10.1002/cncr.33340.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, BispecificAntineoplastic Agents, ImmunologicalDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHematopoietic Stem Cell TransplantationHumansInotuzumab OzogamicinMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRemission InductionRetrospective StudiesTreatment OutcomeWithholding TreatmentYoung AdultConceptsAcute lymphoblastic leukemiaRefractory B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaMedian overall survivalINO groupNovel agentsOverall survivalLymphoblastic leukemiaComplete remissionInotuzumab ozogamicinNA therapyComparable efficacyRelapsed/refractory (r/r) B-cell acute lymphoblastic leukemiaAllogeneic hematopoietic stem cell transplantationCR/CRi rateIncomplete count recovery (CRi) ratesRefractory acute lymphoblastic leukemiaHematopoietic stem cell transplantationNovel agent therapyOutcomes of patientsStem cell transplantationBlinatumomab groupCRi rateTreatment discontinuationAdverse eventsReal-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances 2020, 4: 2308-2316. PMID: 32453836, PMCID: PMC7252553, DOI: 10.1182/bloodadvances.2019001381.Peer-Reviewed Original ResearchConceptsMedian relapse-free survivalAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationRelapse-free survivalAcute lymphoblastic leukemiaOverall survivalCell transplantationRR diseaseClinical trialsComplete remission/complete remissionRetrospective multicenter cohort analysisB-cell acute lymphoblastic leukemiaB-cell acute lymphocytic leukemia patientsCytokine release syndromeIncomplete count recoveryMulticenter cohort analysisAcute lymphocytic leukemia patientsFavorable prognostic significanceLymphocytic leukemia patientsReal-world outcomesConsolidation therapyMRD negativityPrior therapyRelease syndromeComplete remission